Get the Stockscreener App
5.15
0.39%
-0.02
Chimerix Inc stock is traded at $5.15, with a volume of 1.96M.
It is down -0.39% in the last 24 hours and up +34.11% over the past month.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
See More
Previous Close:
$5.17
Open:
$5.2799
24h Volume:
1.96M
Relative Volume:
0.44
Market Cap:
$463.36M
Revenue:
$324.00K
Net Income/Loss:
$-82.10M
P/E Ratio:
-5.5376
EPS:
-0.93
Net Cash Flow:
$-69.18M
1W Performance:
+17.58%
1M Performance:
+34.11%
6M Performance:
+381.31%
1Y Performance:
+332.77%
1-Day Range:
$5.09
$5.2799
1-Week Range:
$4.80
$5.5264
52-Week Range:
$0.75
$5.5264
Chimerix Inc Stock (CMRX) Company Profile
Name
Chimerix Inc
Sector
Industry
Phone
919.806.1074
Address
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Compare CMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
5.15 | 463.36M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-23 | Initiated | Robert W. Baird | Outperform |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Apr-29-21 | Initiated | Maxim Group | Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-31-21 | Initiated | Jefferies | Buy |
| Mar-31-21 | Initiated | Wedbush | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Feb-02-18 | Initiated | H.C. Wainwright | Buy |
| Aug-09-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-23-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-22-16 | Downgrade | Citigroup | Buy → Neutral |
| Dec-29-15 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-15 | Downgrade | FBR Capital | Outperform → Mkt Perform |
| Dec-28-15 | Reiterated | Piper Jaffray | Overweight |
| Dec-17-15 | Initiated | UBS | Buy |
| Oct-05-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-03-15 | Initiated | Citigroup | Buy |
| Aug-18-15 | Initiated | FBR Capital | Outperform |
| Aug-06-15 | Reiterated | Brean Capital | Buy |
| May-11-15 | Reiterated | Brean Capital | Buy |
| Mar-04-15 | Initiated | Barclays | Overweight |
| Feb-12-15 | Reiterated | Stifel | Buy |
| Dec-31-14 | Reiterated | Brean Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
View All
Chimerix Inc Stock (CMRX) Latest News
Vontobel Holding Ltd. Sells 30,000 Shares of Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Chimerix Inc (CMRX)’S 1.77% Increase Makes It Worth Considering Again - Stocks Register
Wedbush Has Positive Outlook for Chimerix FY2025 Earnings - Defense World
Chimerix’s (CMRX) “Buy” Rating Reaffirmed at HC Wainwright - Armenian Reporter
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients (CMRX) - Seeking Alpha
Financial Metrics Unveiled: Chimerix Inc (CMRX)’s Key Ratios in the Spotlight - The Dwinnex
Here's Why Momentum in Chimerix (CMRX) Should Keep going - Nasdaq
What is Wedbush’s Estimate for Chimerix FY2028 Earnings? - Defense World
Evaluating CMRX’s financial ratios for a profitable investment - US Post News
Chimerix stock soars to 52-week high, hits $5.17 - Investing.com India
Chimerix stock soars to 52-week high, hits $5.17 By Investing.com - Investing.com Nigeria
Chimerix Delivers More Than 130% Gain In Less Than 3 Months - RTTNews
Chimerix (NASDAQ:CMRX) Receives Buy Rating from HC Wainwright - Defense World
FDA accepts Chimerix's new drug application for glioma treatment By Investing.com - Investing.com Nigeria
Chimerix’s (CMRX) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Chimerix VP of finance sells $1,359 in stock - MSN
Sector Update: Health Care Stocks Mixed Late Afternoon -February 18, 2025 at 04:06 pm EST - Marketscreener.com
Chimerix Says FDA Grants Priority Review for New Drug Application of Cancer Treatment Dordaviprone; Shares Rise - Marketscreener.com
Chimerix stock gains on FDA review for lead drug (CMRX:NASDAQ) - Seeking Alpha
Wedbush Adjusts Price Target on Chimerix to $7 From $6, Keeps Outperform Rating - Marketscreener.com
Chimerix stock rises on FDA priority review for dordaviprone - Investing.com
Chimerix stock rises on FDA priority review for dordaviprone By Investing.com - Investing.com Nigeria
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma - Marketscreener.com
FDA accepts Chimerix's new drug application for glioma treatment - Investing.com India
Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone - Marketscreener.com
Chimerix CFO sells $10,195 in stock amid tax obligation - MSN
Chimerix CEO Michael Andriole sells $33,282 in stock - MSN
Chimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in Stock - MarketBeat
Chimerix SVP and general counsel sells $7,226 in stock - MSN
Chimerix VP of finance sells $1,359 in stock By Investing.com - Investing.com Australia
Chimerix CFO sells $10,195 in stock amid tax obligation By Investing.com - Investing.com South Africa
Chimerix CEO Michael Andriole sells $33,282 in stock By Investing.com - Investing.com Nigeria
Chimerix SVP and general counsel sells $7,226 in stock By Investing.com - Investing.com South Africa
Chimerix chief medical officer Melemed sells $13,798 in stock - MSN
Chimerix chief medical officer Melemed sells $13,798 in stock By Investing.com - Investing.com Australia
Chimerix Executives Sell Shares to Cover Tax Liabilities - TradingView
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Peapod Lane Capital LLC Buys Shares of 754,566 Chimerix, Inc. (NASDAQ:CMRX) - MarketBeat
Chimerix stock soars to 52-week high, hits $4.3 - MSN
Chimerix stock soars to 52-week high, hits $4.3 By Investing.com - Investing.com Canada
Check out these key findings about Chimerix Inc (CMRX) - SETE News
Chimerix Inc Stock (CMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Chimerix Inc Stock (CMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Andriole Michael T. | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
4.52 |
7,370 |
33,282 |
609,603 |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL |
Feb 13 '25 |
Sale |
4.52 |
1,600 |
7,226 |
213,596 |
| Jakeman David | VP OF FINANCE AND ACCOUNTING |
Feb 13 '25 |
Sale |
4.53 |
300 |
1,360 |
148,987 |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
4.51 |
2,260 |
10,196 |
172,977 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):